Top
image credit: Pixabay

TrakCel, Ori Biotech ink supply chain deal for cell and gene therapy

February 27, 2020

The Ori platform enables therapy developers and contract manufacturers to achieve automated CGT manufacturing in a closed platform, and so the collaboration aims to enable users of the Ori Biotech manufacturing platform to benefit from “live supply chain visibility” through TrakCel software.

The companies plan to work together to give TrakCel customers greater visibility into the manufacturing process via data services within the Ori platform, and to develop suitable points of integration in order for a shared data platform to be available to partners.

Read More on Pharma Times